However, we have previously demonstrated that PARP1 mRNA is increased in pre-treatment OAC tumour samples from patients who exhibited subsequent poor pathological response to CRT, implicating a potential role for PARP1 in the resistance of OAC to CRT [120]. The gene discussed is PARP1; the disease is neoplasm.